Development of multiple complications in type 2 diabetes is associated with the increase of multiple markers of chronic inflammation

• Published in: Journal of clinical laboratory analysis Vol. 22; no. 1; pp. 6 - 13
• Main Authors: Hwang, Jawl-Shan, Wu, Tsu-Lan, Chou, S.C., Ho, C., Chang, Pi-Yueh, Tsao, Kuo-Chien, Huang, Jeng-Yi, Sun, Chien-Feng, Wu, James T.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 2008
• Subjects: Biomarkers - blood; cancer; chronic inflammation; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - pathology; Diabetic Nephropathies - pathology; Disease Progression; Female; Glycated Hemoglobin - metabolism; Humans; Inflammation - blood; Inflammation - complications; inflammation markers; macrovascular disease; Male; microvascular disease; Middle Aged; nephropathy; Original; type 2 diabetes
• ISSN: 0887-8013; 1098-2825
• DOI: 10.1002/jcla.20207

Patients with type 2 diabetes (T2DM) are known at risk for developing cardiovascular disease (CVD), nephropathy, and cancer. We were interested to find out whether multiple markers associated with chronic inflammation are detectable in patients with T2DM and are increased in patients with T2DM who developed additional clinical complications. A sequence of multiple risk markers for atherogenesis, associated with chronic inflammation, was measured in patients with T2DM before and after the development of clinical complications. We found that multiple clinical complications frequently developed simultaneously in patients with T2DM. At the early stage of T2DM, only low levels and low percent elevations of multiple risk markers were detected. However, both the level and the percent elevation of these markers were found to increase with disease progression and the development of clinical complications. We believe that chronic inflammation not only contributes to the pathogenesis of T2DM but also continues to increase in T2DM patients who are developing additional clinical complications. It appears that these multiple markers are potentially useful not only for monitoring the progression of T2DM but also predicting the risk of developing macro‐ and microvascular disease, nephropathy, and cancer. J. Clin. Lab. Anal. 22:6–13, 2008. © 2008 Wiley‐Liss, Inc.